Poster Sessions
Day 1: September 24 (Tuesday) 2024
Room 2 (The Club Fuji C) 17:50-18:50
Poster Session 1: Systemic Therapy [Early Carrer] (1)Chair: Dr. Naoki Morimoto (Japan)
P-01
10019
An Effective Prognostic Risk Model Related to Fatty Acid Metabolism in Hepatocellular
Carcinoma
Dr. Xiaobin Li (China)
P-02
10042
Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced
Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma
Dr. Risako Kohya (Japan)
P-03
10065
The Importance of Assessing Energy Malnutrition in Atezolizumab/Bevacizumab Therapy
Dr. Maho Egusa (Japan)
P-04
10114
Understanding the Disease Stage of Intermediate Stage Hepatocellular Carcinoma (HCC) Analysis of Initial Treatment and Tumor Conditions
Dr. Teppei Akatsuka (Japan)
P-05
10117
Analysis of Immune-mediated Adverse Event Colitis Induced by Combination Therapy with
Durvalumab and Tremelimumab for Advanced Hepatocellular Carcinoma
Dr. Makoto Fujiya (Japan)
P-06
10126
Pathophysiology of Immune Related Liver Injury from a Clinicopathological Perspective
Dr. Ryo Izai (Japan)
P-07
10150
Sorafenib Induced Stevens-Johnson Syndrome after Immune Checkpoint Inhibitor
Treatment in a Patient of Hepatocellular Carcinoma
Dr. Kosuke Kojima (Japan)

Poster Session 2: Basic Research [Early Career]
Chair: Dr. Yasunari Nakamoto(Japan)
P-08
10012
Solanum Torvum Induces Ferroptosis to Suppress Hepatocellular Carcinoma throughSuppression of GPX4 and Activation of HO-1
Dr. Hsiang-Chun Lai (Taiwan)

P-09
10018
Chai Qi Yi Gan Granule Restores Gut Microbial Balance and Modulates Lipid Metabolism to
Suppress Hepatocellular Carcinoma
Dr. Xiaobin Li (China)
P-10
10066
Integrated Single-Cell and Bulk RNA Sequencing Reveals CCR2-High Neutrophils in Gr1+
Myeloid Lineages of CRLM MiceDr. Zijun Yan (China)
P-11
10133
Early Width of Dispersion of Monocytes Complexity (MO-WX) as a Discriminating Tool of
Hepatocellular Carcinoma in Liver Cirrhotic: A Pilot Study of Novel Marker with
Leukocytes Cell Population Data
Dr. Dwijo A Sindhughosa (Indonesia)
P-12
10153
Biflavonoid Derivatives as Potential CDK1 Inhibitors in Hepatocellular Carcinoma:
Investigation via Virtual Screening and Molecular Interaction Analysis
Dr. Reny Rosalina (Indonesia)
P-13
10125
Withdrawn
P-14
10049
Dietary Elaidic Acids Promotes Malignant Behavior of HepG2 Cells via NF-kappaB Signaling
Pathway
Dr. Xiao Hu (China)

Poster Session 3: Liver Cirrhoss and Portal Hypertension [Early Career]
Chair: Dr. Masanori Atsukawa (Japan)
P-15
10015
Association between Osteosarcopenia and Prognosis in Liver Cirrhosis Complicated with
Portal Hypertension
Dr. Arisa Saito (Japan)
P-16
10017
Reasons for Liver Regeneration Failure, How to Save it?
Dr. Bowen Liu (China)
P-17
10050
Long-term L-carnitine Supplementation Suppresses Skeletal Muscle Mass Loss by Decreasing
the Expression of Interleukin-6 in Patients with Hepatocellular Carcinoma
Dr. Yu Takeda (Japan)
P-18
10052
Effect of MAFLD Criteria on Postoperative Recurrence of NBNC-HCC
Dr. Yusuke Johira (Japan)

P-19
10092
Effectiveness of Multidisciplinary Inpatient Treatment with Personalized Diet and Exercise
Therapy for Steatotic Liver Disease
Dr. Eriksson Yasuka (Japan)
P-20
10156
Virtual Screening of Resveratrol-derived Compounds for Targeting the TGF-&beta;1
Receptor in Liver Fibrosis
Dr. Rian Ka Praja (Indonesia)
P-21
10144
Mathematical Modelling for Investigating the Inconsistencies between Transient
Elastography and Liver Biopsy Results in Assessing Liver Fibrosis in Patients with Chronic
Viral Hepatitis
Dr. Prihantini Prihantini (Indonesia)

Poster Session 4: Case Report [Early Career] (1)Chair: Dr. Kazuyoshi Ohkawa (Japan)
P-22
10051
A Resected Case of Hepatocellular Carcinoma with Paraneoplastic Syndrome
Dr. Mai Totsuka (Japan)
P-23
10056
A Case of Hepatic Leiomyosarcoma Diagnosed through Autopsy
Dr. Kensho Kubo (Japan)
P-24
10079
A Case of Hilar Bile Duct Carcinoma with Severe Eosinophilia
Dr. Terunao Iwanaga (Japan)
P-25
10109
A Case of Hepatic Reactive Lymphoid Hyperplasia Diagnosed by Post-RFA Biopsy Specimen
Dr. Masaki Kawabata (Japan)
P-26
10111
Cytokine Release Syndrome Caused by the Combination Immunotherapy for Advanced
Hepatocellular Carcinoma
Dr. Sae Yumita (Japan)

Poster Session 5: Case Report [Early Career] (2)Chair: Dr. Yoshiyuki Ueno (Japan)
P-27
10006
A Case of Hepatocellular Carcinoma that could be Radically Resected after Combined
Therapy with Lenvatinib and TACE
Dr. Ryo Yano (Japan)
P-28
10035
A Case of Consciously Selected LEN-TACE for Unresectable HCC Combined with Acquired
Thrombotic Thrombocytopenic Purpura
Dr. Tsuyoshi Fujioka (Japan)

P-29
10093
Hepatocellular Carcinoma with Long Complete Response after Liver and Lung Resectionsand Lenvatinib
Dr. Shohe Kobe (Japan)
P-30
10135
Anti-HCV Treatment Using Direct-acting Antivirals during Systemic Immunotherapy for
Unresectable Hepatocellular Carcinoma may Contribute to Improving Long-term Prognosis:
A Case Report
Dr. Wataru Ueno (Japan)
P-31
10148
A Case of Fatal Immune-Mediated Myocarditis Following Durvalumab and Tremelimumab
Combination Therapy (DT) for Multiple Hepatocellular Carcinomas
Dr. Ryo Saito (Japan)

Poster Session 6: Systemic Therapy (1)Chair: Dr. Toshifumi Tada (Japan)
P-32
10004
Impact of Atezolizumab + Bevacizumab Combination Therapy on Health-related Quality ofLife and Relationship with Prognosis in Patients with Advanced Hepatocellular Carcinoma
Dr. Masako Shomura (Japan)
P-33
10038
Cytokine Analysis as a Predictive Biomarker of Response to Treatment with Atezolizumab
and Bevacizumab in Advanced Hepatocellular Carcinoma
Dr. Satoshi Kobayashi (Japan)
P-34
10055
Pretreatment Predictors of Response to Combination Therapy with
Atezolizumab/Bevacizumab in Advanced Stage Hepatocellular Carcinoma
Dr. Norikazu Tanabe (Japan)
P-35
10141
Clinical Significance of Oncological Resectability Criteria in Patients Treated with
Atezolizumab and Bevacizumab
Dr. Yutaka Yasui (Japan)
P-36
10155
Outcomes of Atezolizumab Plus Bevacizumab (Atezo/Bev) Therapy for Hepatocellular
Carcinoma (HCC) without Macroscopic Vascular Invasion (MVI) or Extrahepatic Spread(EHS) ~ Focus on Tumor Factors
Dr. Michihisa Moriguchi (Japan)
P-37
10161
CyTOF Reveals Platelet Subtype Changes Predicting the Efficacy of Combined
Immunotherapy and Targeted Therapy in Liver Cancer
Dr. Junfeng Lu (China)

Poster Session 7: Systemic Therapy (2)Chair: Dr. Hidenori Nagai (Japan)
P-38
10059
Predictive Factors for Objective Response Rate in Patients with Unresectable Hepatocellular
Carcinoma Treated with Durvalumab plus Tremelimumab Therapy
Dr. Yuki Shirane (Japan)
P-39
10062
Efficacy and Safety of Durvalumab plus Tremelimumab for Advanced Hepatocellular
Carcinoma with Esophageal Varices
Dr. Naoshi Odagiri (Japan)
P-40
10069
Effective Monitoring of Durvlumab plus Tremelimumab Therapy Using Tumor Marker
Dr. Issei Saeki (Japan)
P-41
10089
Efficacy and Safety of Immunotherapy for Real-World Elderly Patients with Unresectable
Hepatocellular Carcinoma in Japan
Dr. Shun Kaneko (Japan)
P-42
10110
Treatment Efficacy in Durvalumab plus Tremelimumab Therapy for Unresectable
Hepatocellular Carcinoma with Previous Immune Check Point Inhibitor
Dr. Nami Mori (Japan)

Poster Session 8: Surgical Resection, Transplantation, and Local Therapy (1)Chair: Dr. Hiroaki Nagano (Japan)
P-43
10007
Surgical Outcomes of Combined Hepatocellular-Cholangiocarcinoma in Comparison to
Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: a Propensity-Score
Matched Analysis
Dr. Hae Won Lee (Korea)
P-44
10030
Short- and Long-term Outcomes of Laparoscopic Liver Resection for Non-alcoholic Fatty
Liver Disease-associated Hepatocellular Carcinoma
Dr. Yukihiro Watanabe (Japan)
P-45
10054
Significance of Repeated Laparoscopic Liver Resection for Recurrent HCC after Curative
Treatment
Dr. Yuji Iimuro (Japan)
P-46
10057
Attenuation of Hepatic Ischemia-reperfusion Injury Associated with Liver Transplantation
by Curcumin in Rodents via Anti-inflammatory Action
Dr. Ekta Yadav (India)

P-47
10082
Current Status of Tumor Ablation in Japan and the Japan Academy of Tumor Ablation(JATA)
Dr. Shuichiro Shiina (Japan)
P-127 10129
Efficacy of HAIC with 3D-CRT for Unresectable Advanced Hepatocellular Carcinoma
Complicated by Major Vascular Tumor Thrombosis
Dr. Joji Tani (Japan)

Poster Session 9: Clinical Research of Liver Cancer (1)Chair: Dr. Michiaki Unno (Japan)
P-48
10008
Clinical Significance of Biliary Invasion at Diagnosis in Barcelona Clinic Liver Cancer Stage
B-C Hepatocellular Carcinoma: a Nationwide Cohort Analysis in South Korea
Dr. Sunmin Park (Korea)
P-49
10020
Clinical Characteristics and Prognosis of Hepatocellular Carcinoma Patients without Liver
Fibrosis
Dr. Fujimasa Tada (Japan)
P-50
10046
Second-Line Treatment Strategy in Unresectable Hepatocellular Carcinoma after First-LineAtezolizumab Plus Bevacizumab
Dr. Kunihide Mohri (Japan)
P-51
10074
Influence of Gender Differences and Aging on the Clinical Background of Patients with
Hepatocellular Carcinoma
Dr. Atsushi Hiraoka (Japan)
P-52
10088
Real World Data of Cabozantinib in Patients with Hepatocellular Carcinoma: Focusing on
Dose Setting and Modification
Dr. Hironao Okubo (Japan)
P-53
10136
Comprehensive Analysis of Reaching Radiological Cancer-free Status in Advanced-stage
Hepatocellular Carcinoma
Dr. Keisuke Koroki (Japan)
P-54
10152
Real-world Experience of Cabozantinib after Immnotherapy in Patients with Unresectable
Hepatocellular Carcinoma
Dr. Kaoru Tsuchiya (Japan)

Poster Session 10: Liver Cirrhosis and Portal Hypertension
Chair: Dr. Keisuke Kakisaka (Japan)
P-55
10022
Hepatocellular Carcinoma is a Prognostic Factor in Patients Treated for Esophagogastric
VaricesDr. Akira Uchiyama (Japan)
P-56
10037
Subharmonic-Aided Pressure Estimation (SHAPE); A New Noninvasive Technique for
Diagnosing Portal Hypertension
Dr. Yoshiko Nakamaura (Japan)
P-57
10058
Enhancing Bioavailability of Furosemide for the Management of Portal Hypertension Using
Self Nano Emulsifying Drug Delivery System
Dr. Pankajkumar Yadav (India)
P-58
10073
Significance of Neutrophil-to-lymphocyte Ratio in Bleeding after Endoscopic Treatment of
Cirrhotic Patients with Esophageal Varices
Dr. Kazuto Takahashi (Japan)
P-59
10083
Regional Difference for Morbidity of Liver Cancer and Spread of Ultrasound Elastography inJapan: A Real-world Evidence Using National Database of Health Insurance Claims
Dr. Masahito Nakano (Japan)
P-60
10120
Efficacy and Safety of Avatrombopag
Dr. Rie Goka (Japan)
P-61
10143
The Diagnostic Ability of the Prediction for Hepatocarcinogenesis Using Non-invasive Scoring
Systems Including VCTE and CAP in Patients with MASLD/MASH
Dr. Takashi Nishimura (Japan)

Poster Session 11: MASLD
Chair: Dr. Takumi Kawaguchi (Japan)
P-62
10011
Effects of SGLT2 Inhibitors on the Onset of Extrahepatic Cancer in Type 2 Diabetic Patientswith MASLD: A Nationwide Database Study in Japan
Dr. Takumi Kawaguchi (Japan)
P-63
10090
Effect of MAFLD on Hepatocarcinogenesis in HBeAg-negative Patients with Undetectable
HBV-DNA under NA Therapy: A Multicenter Study
Dr. Keisuke Amano (Japan)

P-64
10116
Modified Forms of Secondary Bile Acid Levels Could be Biomarkers of Hepatocellular
Carcinoma Pathogenesis in MASLD PatientsDr. Yoshimi Yukawa-Muto (Japan)
P-65
10122
Efficacy of Measuring Natural Killer-activating Receptor Ligands to Predict the Pathogenesisof Metabolic Dysfunction-associated Steatotic Liver Disease
Dr. Jun Arai (Japan)

Poster Session 12: Basic Research (1)Chair: Dr. Naoshi Nishida (Japan)
P-66
10026
Can the Blood Coagulation Factor Von Willebrand Factor be a Predictor of Response to
Atezolizumab plus Bevacizumab Combination Therapy for Advanced Hepatocellular
Carcinoma?
Dr. Naoki Nishimura (Japan)
P-67
10053
Interaction of PKR and 4.1R Promotes Anchorage-independent Growth of Hepatocellular
Carcinoma
Dr. Yusuke Okujima (Japan)
P-68
10108
Hepatoma-derived Growth Factor as a Possible Therapeutic Target for Hepatocellular
Carcinoma
Dr. Hirayuki Enomoto (Japan)
P-69
10160
Morphological Architectures of Patient-derived Hepatocellular Carcinoma Organoids with
GSK3-beta Expression Dependent Variability According to Lenvatinib ResistanceDr. Jun Yong Park (Korea)
P-70
10166
Role of Erastin in Intestinal Injury Following Perioperative Liver Transplantation via
Ferroptosis in Animals
Dr. Deepika Singh (India)

Poster Session 13: Case Report (1)Chair: Dr. Tomokazu Kawaoka (Japan)
P-71
10043
A Case of Child-Pugh C with Advanced HCC Treated by a Hepatologist
Dr. Shuntaro Obi (Japan)
P-72
10045
Atezolizumab and Bevacizumab following Stereotactic Body Radiotherapy for Two Patientswith Unresectable Hepatocellular Carcinomas with Vp4/Vv3 and Vp3 Macrovascular
Invasion
Dr. Satoshi Komiyama (Japan)

P-73
10060
A Case Study of Advanced Hepatocellular Carcinoma Treated with Radiotherapy andChemotherapy
Dr. Hideo Yoshida (Japan)
P-74
10063
A Case of Hepatocellular Carcinoma with Vp4 Treated with Durvalumab plus
Tremelimumab after Lenvatinib plus Hepatic Artery Infusion Chemotherapy
Dr. Mariko Nishioka (Japan)
P-75
10102
Curative Treatment of Two Hepatocellular Carcinoma Cases with Radiofrequency Ablation
Following Atezolizumab Plus Bevacizumab
Dr. Kosuke Matsumoto (Japan)
P-76
10145
A Case of Vp4 Hepatocellular Carcinoma Successfully Treated with Hepatic Arterial Infusion
Chemotherapy Combined with Radiotherapy (HAIC-RT) and Subsequent Molecular
Targeted Therapy
Dr. Hirotoshi Ebinuma (Japan)
P-77
10158
A Case of a Hepatocellular Carcinoma Associated with Autoimmune Hepatitis with
Atezolizumab and Bevacizumab Therapy
Dr. Kazuo Tsubura (Japan)

Poster Sessions
Day 2: September 25 (Wednesday) 2024
Room 2 (The Club Fuji C) 16:20-17:20
Poster Session 14: Systemic Therapy [Early Carrer] (2)Chair: Dr. Teiji Kuzuya (Japan)
P-78
10014
Comparing Clinical Outcomes between PD-L1 and PD-1 Inhibitors Plus Anti-VEGF
Antibody Combined with Hepatic Arterial Interventional Therapies in Unresectable HCC: A
Single-center, Real-world Study
Dr. Yangxun Pan (China)
P-79
10080
The Efficacy and Safety of Durvalumab + Tremelimumab for Unresectable Hepatocellular
Carcinoma
Dr. Aiko Tanaka (Japan)
P-80
10113
Exploring the Safety and Efficacy of Durvalumab Monotherapy for Advanced Hepatocellular
Carcinoma Patients Ineligible for Combined Immunotherapy
Dr. Chihiro Miwa (Japan)

P-81
10123
Integrative Deep Learning Framework for Investigating the Role of Tumor-AssociatedMacrophages in Hepatocellular Carcinoma Metastasis Using Single-Cell Multi-Omics andSpatial Transcriptomics
Dr. Rifaldy Fajar (Indonesia)
P-82
10127
Re-positioning of Hepatic Arterial Infusion Chemotherapy in the Era of Systemic Therapy
Dr. Takahiro Tsuchiya (Japan)
P-83
10139
Significance of Two Patterns of ICI Rechallenge with STRIDE Therapy in Advanced
Hepatocellular Carcinoma
Dr. Takuya Yonemoto (Japan)
P-84
10159
Real-World Outcomes of Durvalumab Plus Tremelimumab Combination Therapy (DTTherapy) in Unresectable Hepatocellular Carcinoma: Analysis by Treatment Line andPrognostic Factors
Dr. Naoki Uchihara (Japan)

Poster Session 15: Surgical Resection, Transplantation, and Local Therapy[Early Carrer]
Chair: Dr. Mitsuo Shimada (Japan)
P-85
10013
Challenges and Scope in Deceased Donor Liver Transplantation in Bangladesh: The
Dynamics of Ethics, Socio-culture and Religion
Dr. Md Ismail Gazi (Bangladesh)
P-86
10025
Influence of RFA on Liver Reserve Function in Child-Pugh B Patients with HCC within
Milan Criteria
Dr. Ayaka Nakamura (Japan)
P-87
10040
Indocyanine Green Applied in Unresectable Hepatocellular Carcinoma after Neoadjuvant
Combination Therapy
Dr. Man Luo (China)
P-88
10077
How Far Economics Analysis Does Matter: The Relation of Macroeconomic, Education, andWealth with Liver Transplantation
Dr. Rosinta H.P. Purba (Indonesia)
P-89
10078
Epidemiology and Risk Factors Relating to Post-Liver Transplantation (LT) in Children
Dr. Lintong H. Simbolon (Indonesia)
P-90
10084
Outcome of Hepatectomy after Systemic Therapy in Hepatocellular Carcinoma: A JapaneseMulti-Center Study
Dr. Norifumi Iseda (Japan)

P-91
10128
Efficacy and Safety of Superselective Transarterial Chemoembolization Combined with
Systemic Therapy for Unresectable Hepatocellular Carcinoma: A Single-Center Retrospective
Cohort Study
Dr. Takuya Watanabe (Japan)

Poster Session 16: Hepatobilialy Malignancy [Early Career]
Chair: Dr. Manabu Morimoto (Japan)
P-92
10003
Targeting Ferroptosis with Polymerized Platinum (IV) Prodrugs Nanoparticles with
Everolimus for Enhancing Therapeutic Efficacy on Cholangiocarcinoma
Dr. Yang Chen (China)
P-93
10010
Examination of Interactions Affecting Epithelial-mesenchymal Transition in Intrahepatic
Colangiocarcinoma
Dr. Takahiro Haruna (Japan)
P-94
10031
Perioperative Outcomes of Robotic Radical Resection for Gallbladder Cancer: A Singlecenter Case Series
Dr. Ji-Min Dai (China)
P-95
10068
High-precision Genomic Analysis Using the Molecular Barcoding Method in Liquid Biopsy of
Pancreaticobiliary Cancer
Dr. Miho Sakai (Japan)
P-96
10115
Effects of SGLT2 Inhibitors on Cholangiocarcinoma in Cell Lines and an Animal Model
Dr. Daisuke Minowa (Japan)
P-97
10131
Blood CGP Pave the Way for Genomic Therapy in Biliary Tract Cancer ?
Dr. Yoshiki Ogane (Japan)
P-98
10132
The Usefulness of Tissue CGP in Real-World Biliary Tract Cancer Treatment
Dr. Yu Sekine (Japan)

Poster Session 17: Viral Hepatitis [Early Carrer]
Chair: Dr. Masahito Shimizu (Japan)
P-99
10033
A Study on Hepatocellular Carcinoma and Intestinal Microflora in Patients with Chronic
Hepatitis B
Dr. Yusuke Tanaka (Japan)

P-100 10034
Clinical Feature of Hepatocellular Carcinoma Patients with Overall Survival (10 Years or
More)
Dr. Takuya Matsuda (Japan)
P-101 10036
Treatment Outcomes of Patients with Unresectable Hepatocellular Carcinoma: A Single
Center Retrospective Cohort Study
Dr. Christmae M. Solon (Philippines)
P-102 10048
HBV preS1/HBsAg Ratio is a Predictive Marker for the Occurrence of Hepatocellular
Carcinoma
Dr. Masanari Kosaka (Japan)
P-103 10157
Promising Antiviral siRNAs for Targeting NS4A and NS5A in Hepatitis C Virus Genotype 1
Dr. Rian Ka Praja (Indonesia)
P-104 10162
The Correlation between Interleukin-6 and the Progression of Chronic Hepatitis B
Dr. Mohamed S. Mohaboob Ali (Malaysia)
P-105 10142
An Advanced Predictive System Using Gradient Boosting Machines (GBM) to Forecast
Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Virus Infection
Dr. Prihantini Prihantini (Indonesia)

Poster Session 18: Case Report [Early Career] (3)Chair: Dr. Kazuhiro Nouso (Japan)
P-106 10103
A Case of Atezolizumab-Bevacizumab Combination Therapy with Good Long-Term
Prognosis Despite Prolonged Bevacizumab Withdrawal
Dr. Fumiya Suzuki (Japan)
P-107 10134
A Case of Hepatocellular Carcinoma with Bone Metastasis Achieved Complete Response
Using Stereotactic Radiotherapy and Lenvatinib, Following Anti-PD-L1 Antibody-induced
Psoriasis-like Dermatitis
Dr. Chikako Nagao (Japan)
P-108 10146
A Case of Hepatocellular Carcinoma with Multiple Pulmonary Metastatic Recurrences at
Distant Stage after Radical Cure
Dr. Akihiko Nishimura (Japan)
P-109 10147
Remarkable Response to Atezolizumab plus Bevacizumab Therapy after Psuedo-progression,
Followed by Phenotypic Change in Conversion Surgery: A Unique Case of Hepatocellular
Carcinoma
Dr. Midori Sawada (Japan)

P-110 10169
A Cholangiolocellular Carcinoma Case Showing Slow Tumor Growth and Marked
Intratumoral Lymphocyte Infiltration, with a Favorable Outcome
Dr. Ayaka Gamo (Japan)

Poster Session 19: Systemic Therapy (3)Chair: Dr. Hayato Hikita (Japan)
P-111 10001
Survey of Systemic Drug Therapy for Unresectable Hepatocellular Carcinoma in Nondesignated Regional Cancer Treatment Hospital in Japan
Dr. Hidehiro Kamezaki (Japan)
P-112 10044
Hepatic Dysfunction in 879 ICI-treated Patients; Does Referral to a Hepatologist ImproveOS?
Dr. Kaori Matsumoto (Japan)
P-113 10061
Atezolizumab plus Bevacizumab Shows PFS Benefit in mALBI Grade 2 HCC
Dr. Shunji Watanabe (Japan)
P-114 10075
Results of Atezolizumab Combined with Bevacizumab for Advanced Hepatocellular
Carcinoma in Vietnamese Patients
Dr. Hang T. Hoang (Viet Nam)
P-115 10099
Assessment of Macrovascular Invasion in Advanced Hepatocellular Carcinoma: ClinicalImplications and Treatment Outcomes with Systemic Therapy
Dr. Masanori Inoue (Japan)
P-116 10107
A Retrospective Analysis of Liver Volume Decrease in Advanced Hepatocellular Carcinoma
Patients Treated with Atezolizumab plus Bevacizumab and Lenvatinib
Dr. Tomoharu Yamada (Japan)
P-117 10121
Diagnosis Triggers and Outcomes in Patients Treated with Atezolizumab/Bevacizumab as
Initial Treatment for Hepatocellular Carcinoma
Dr. Teiji Kuzuya (Japan)

Poster Session 20: Systemic Therapy (4)Chair: Dr. Tatehiro Kagawa (Japan)
P-118 10027
Systemic Therapy for Unresectable HCC Combination with TACE (Lenvatinib or
Atezolizumab/Bevacizumab)
Dr. Ryu Sasaki (Japan)

P-119 10100
Efficacy of Lenvatinib + New FP Combination Therapy in the Treatment of Unresectable
Advanced Hepatocellular Carcinoma
Dr. Susumu Maruta (Japan)
P-120 10124
Combining On-demand Locoregional Treatment for Drug-resistant Lesions during
Atezolizumab and Bevacizumab Therapy in Unresectable Hepatocellular Carcinoma
Dr. Tasuku Nakabori (Japan)
P-121 10138
Effectiveness of Immune Checkpoint Inhibitor Therapy with Locoregional Therapy Versus
ICI Alone in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
Dr. Yasuhide Motoyoshi (Japan)
P-122 10149
Is Lenvatinib Resumption Necessary after Lenvatinib-TACE Combination Treatment ?
Dr. Rie Sugimoto (Japan)
P-123 10165
Effect of Radiofrequency Ablation on the Therapeutic Efficacy of Atezolizumab/Bevacizumab
Combination Therapy
Dr. Masahiko Tameda (Japan)

Poster Session 21: Surgical Resection, Transplantation, and Local Therapy (2)Chair: Dr. Shuntaro Obi (Japan)
P-124 10029
Carbon-ion Radiotherapy for Hepatocellular Carcinoma 4 cm or Larger
Dr. Tetsuro Isozaki (Japan)
P-125 10081
Ablation Training Program for Liver Tumors at Juntendo
Dr. Shuichiro Shiina (Japan)
P-126 10098
LI-RADS CT/MRI Radiation Treatment Response Assessment Version 2024: Evaluation after
Transarterial Radioembolization for Hepatocellular Carcinoma
Dr. Sunyoung Lee (Korea)
P-128 10151
Clinical Outcomes with Stereotactic Body Radiation Therapy in Patients with Hepatocellular
Carcinoma
Dr. Puja Sahai (India)

Poster Session 22: Clinical Research of Liver Cancer (2)Chair: Dr. Hirayuki Enomoto (Japan)
P-129 10071
Efficacy of the GFAD Index as a New Indicator for the Early Diagnosis of Non-Viral
Hepatocellular Carcinoma
Dr. Akiyo Ishiguro (Japan)

P-130 10087
The Association between the Prognoses and Systemic Chemotherapy According to the
Oncological Conditions in Patients with Colorectal Liver Metastases
Dr. Nozomu Sakai (Japan)
P-131 10095
Quality of Life in Patients with Hepatobiliary Cancers
Dr. Asmin Valiyagath (India)
P-132 10097
Does Transcatheter Arterial Chemoembolization for Liver Metastasis in Neuroendocrine
Tumors Reduce Hepatic Reserve?
Dr. Asako Nogami (Japan)
P-133 10101
Clinical Outcome of GCD Therapy for Unresectable Intrahepatic Cholangiocarcinoma
Dr. Hiroki Inada (Japan)
P-134 10105
Etiological Transitions in Patients with Liver Cirrhosis and Hepatocellular Carcinoma: aSingle-center Study from an Institution Located in a District with a High Prevalence of Viral
Hepatitis
Dr. Hirayuki Enomoto (Japan)
P-135 10140
Atezolizumab plus Bevacizumab for Combined Hepatocellular Cholangiocarcinoma
Dr. Tomoyuki Satake (Japan)

Poster Session 23: Viral Hepatitis
Chair: Dr. Norio Akuta (Japan)
P-136 10070
A Novel Hepatitis Delta virus (HDV) in Vitro Carcinogenesis Model
Dr. Shinya Sato (Japan)
P-137 10091
The Prognosis of Hemodialyzed Patients with Hepatitis C Treated by Direct Acting Antivirals
Dr. Hitoshi Takagi (Japan)
P-138 10094
Comprehensive RNA-seq Analysis of HCV-infected Cells and Specimens from Patients with
Liver Cancer after HCV eradication to Elucidate Liver Carcinogenesis
Dr. Katsuya Nagaoka (Japan)
P-139 10096
Epidemiology of Liver Disease in Kerala: A Retrospective Study
Dr. Sabin Katpattil (India)

Poster Session 24: Basic Research (2)Chair: Dr. Tsutomu Masaki (Japan)
P-140 10021
Oncolytic Activity of a Chimeric Influenza A Virus Carrying a Human CTLA4 Antibody in
Hepatocellular Carcinoma
Dr. Penghui Yang (China)
P-141 10024
Cabozantinib Prevents the Progression of Metabolic Dysfunction-associated Steatohepatitis
by Inhibiting the Activation of Hepatic Stellate Cell and Macrophage and Attenuating
Angiogenic Activity
Dr. Takuya Matsuda (Japan)
P-142 10028
Extracellular Vesicles-mediated Mutant β-catenin Transfer from Hepatocyte Activates
Hepatic Stellate Cells in Tumor Microenvironment
Dr. Yu Ota (Japan)
P-143 10032
Tumor-derived CCL15 Regulates RNA m6A Methylation in Cancer-associated Fibroblasts toPromote Hepatocellular Carcinoma Growth
Dr. Yueguo Li (China)
P-144 10112
A Near-infrared-modulated System Enabling Efficient Delivery of Glucose Derivative as a
New Therapeutic Strategy for Liver Cancer
Dr. Sohji Nishina (Japan)
P-145 10164
Chemoprotective Effect of Crocetin-Dextrin Nano-formulation against N-diethylnitrosamine
Induced Hepatocellular Carcinoma in Rats via Mitochondrial Apoptosis andPI3K/Akt/mTOR Signaling Pathways
Dr. Vikas Kumar (India)
P-146 10168
The Whole Genome and RNA Sequence Analysis on the Hepatocellular Carcinoma Derived
from the Patients with Fontan-associated Liver Disease
Dr. Taiji Yamazoe (Japan)

Poster Session 25: Basic Research (3)Chair: Dr. Makoto Chuma (Japan)
P-147 10009
Development of a Small Animal Model for Fatty Liver-related Hepatocarcinogenesis
Research
Dr. Daiki Miki (Japan)
P-148 10039
WithdrawnP-149 10047
Inhibitory Effects of Putrescine on Metabolic Dysfunction-associated Steatepatitis in MiceDr. Erdenetsogt Dungubat (Japan)
P-150 10119
Exploring the Link Between Mitochondrial ROS, Peroxiredoxin V, and Liver Fibrosis in
Metabolic Associated Fatty Liver DiseaseDr. Hyun Ae Woo (Korea)
P-151 10167
Efalizumab Modulates HAT1 and Increases IL-9 to Induce Ferroptosis and CD8+ T Cell
Immunological Activity in Hepatocellular Carcinoma
Dr. Manvendra Singh (India)
P-152 10170
Invasive Hepatic Stellate Cell Shapes Immunovascular Landscape of Hepatocellular
Carcinoma
Dr. Michitaka Matsuda (Japan)
P-159 10171
Investigation of TEAD Inhibitor for Hepatocellular Carcinoma Treatment
Dr. Yoshinobu Saito (Japan)

Poster Session 26: Case Report (2)Chair: Dr. Takahiro Yamazaki (Japan)
P-153 10023
Myositis Induced by an Immune Checkpoint Inhibitor in a Hepatocellular Carcinoma Patientwith Primary Biliary Cirrhosis: A Case Report
Dr. Naoya Tsuzuki (Japan)
P-154 10067
A Case of Unresectable Hepatocellular Carcinoma Complicated by Cerebral Hemorrhage
after Combined Therapy with Atezolizumab and Bevacizumab
Dr. Tamami Abe (Japan)
P-155 10072
A Case of Duodenal Bleeding from Invasion of Lymph Node Metastasis during Combination
Therapy with Atezolizumab and Bevacizumab for Hepatocellular Carcinoma
Dr. Kyoko Hoshikawa (Japan)
P-156 10076
A Case of Hepatic Hemangiosarcoma Followed by Long-term Imaging
Dr. Takayuki Kogure (Japan)
P-157 10106
A Case of Hepatic Focal Nodular Hyperplasia after Liver Transplantation
Dr. Kenichi Nakamura (Japan)
P-158 10137
A Case of Scirrhous Hepatocellular Carcinoma Discovered after Combined Immunotherapy
for Hepatocellular Carcinoma
Dr. Yuta Maruki (Japan)